Caseware UK (AP4) 2022.0.179 2022.0.179 2023-07-312023-07-312022-08-01falseNo description of principal activity22truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 10272401 2022-08-01 2023-07-31 10272401 2021-08-01 2022-07-31 10272401 2023-07-31 10272401 2022-07-31 10272401 c:Director1 2022-08-01 2023-07-31 10272401 c:Director2 2022-08-01 2023-07-31 10272401 d:OtherPropertyPlantEquipment 2022-08-01 2023-07-31 10272401 d:OtherPropertyPlantEquipment 2023-07-31 10272401 d:OtherPropertyPlantEquipment 2022-07-31 10272401 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2022-08-01 2023-07-31 10272401 d:CurrentFinancialInstruments 2023-07-31 10272401 d:CurrentFinancialInstruments 2022-07-31 10272401 d:CurrentFinancialInstruments d:WithinOneYear 2023-07-31 10272401 d:CurrentFinancialInstruments d:WithinOneYear 2022-07-31 10272401 d:ShareCapital 2023-07-31 10272401 d:ShareCapital 2022-07-31 10272401 d:RetainedEarningsAccumulatedLosses 2023-07-31 10272401 d:RetainedEarningsAccumulatedLosses 2022-07-31 10272401 c:FRS102 2022-08-01 2023-07-31 10272401 c:AuditExemptWithAccountantsReport 2022-08-01 2023-07-31 10272401 c:FullAccounts 2022-08-01 2023-07-31 10272401 c:PrivateLimitedCompanyLtd 2022-08-01 2023-07-31 10272401 e:PoundSterling 2022-08-01 2023-07-31 iso4217:GBP xbrli:pure

Registered number: 10272401










ONYX MEDICAL LTD








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 JULY 2023

 
ONYX MEDICAL LTD
 
  
CHARTERED ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF ONYX MEDICAL LTD
FOR THE YEAR ENDED 31 JULY 2023

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Onyx Medical Ltd for the year ended 31 July 2023 which comprise  the Balance sheet and the related notes from the Company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW)we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com /regulation.

This report is made solely to the Board of directors of Onyx Medical Ltd, as a body, in accordance with the terms of our engagement letter dated 16th February 2018Our work has been undertaken solely to prepare for your approval the financial statements of Onyx Medical Ltd and state those matters that we have agreed to state to the Board of directors of Onyx Medical Ltd, as a body, in this report in accordance with ICAEW Technical Release TECH07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Onyx Medical Ltd and its Board of directors, as a body, for our work or for this report. 

It is your duty to ensure that Onyx Medical Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Onyx Medical Ltd. You consider that Onyx Medical Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or review of the financial statements of Onyx Medical Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

  



MWS
 
Chartered Accountants
  
Kingsridge House
601 London Road
Westcliff-on-sea
Essex
SS0 9PE
11 March 2024
Page 1

 
ONYX MEDICAL LTD
REGISTERED NUMBER: 10272401

BALANCE SHEET
AS AT 31 JULY 2023

2023
2022
Note
£
£

Fixed assets
  

Tangible assets
 4 
198
1,191

  
198
1,191

Current assets
  

Cash at bank and in hand
 5 
4,010
2,775

  
4,010
2,775

Creditors: amounts falling due within one year
 6 
(1,392)
(1,740)

Net current assets
  
 
 
2,618
 
 
1,035

Total assets less current liabilities
  
2,816
2,226

Provisions for liabilities
  

Deferred tax
  
(226)
(226)

  
 
 
(226)
 
 
(226)

Net assets
  
2,590
2,000


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
2,490
1,900

  
2,590
2,000


Page 2

 
ONYX MEDICAL LTD
REGISTERED NUMBER: 10272401

BALANCE SHEET (CONTINUED)
AS AT 31 JULY 2023

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 11 March 2024.




Dr P Beegoo
Dr M Metcalfe
Director
Director

The notes on pages 4 to 8 form part of these financial statements.

Page 3

 
ONYX MEDICAL LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

1.


General information

Onyx Medical Limited is a private company limited by shares and incorporated in England.
Its registered office is 601 London Road, Westcliff-on-Sea, Essex, SS0 9PE.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 4

 
ONYX MEDICAL LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

2.Accounting policies (continued)

 
2.3

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

 
2.4

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Website
-
on a straight line basis over 5 years

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 5

 
ONYX MEDICAL LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

2.Accounting policies (continued)

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.7

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

 
2.8

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees




The average monthly number of employees, including directors, during the year was 2 (2022 - 2).

Page 6

 
ONYX MEDICAL LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

4.


Tangible fixed assets





Website

£



Cost or valuation


At 1 August 2022
4,963



At 31 July 2023

4,963



Depreciation


At 1 August 2022
3,772


Charge for the year on owned assets
993



At 31 July 2023

4,765



Net book value



At 31 July 2023
198



At 31 July 2022
1,191


5.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
4,010
2,775

4,010
2,775



6.


Creditors: Amounts falling due within one year

2023
2022
£
£

Corporation tax
372
761

Other creditors
570
569

Accruals and deferred income
450
410

1,392
1,740


Page 7

 
ONYX MEDICAL LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

7.


Related party transactions

During the year the following transactions took place with the directors:
Dividends: M Metcalfe £nil (2022:£2,000)
Dividends: P Beego £nil (2021: £2,000)


Page 8